BID regulation by p53 contributes to chemosensitivity

被引:331
作者
Sax, JK [1 ]
Fei, PW
Murphy, ME
Bernhard, E
Korsmeyer, SJ
El-Deiry, WS
机构
[1] Univ Penn, Sch Med, Dept Med,Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Pharmacol, Howard Hughes Med Inst,Lab Mol Oncol & Cell Cycle, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Genet, Howard Hughes Med Inst,Lab Mol Oncol & Cell Cycle, Philadelphia, PA 19104 USA
[4] Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA
[5] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol,Howard Hughes Med Inst, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Howard Hughes Med Inst, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/ncb866
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The role of the p53 protein (encoded by TP53) in tumour suppression relies partly on the ability of p53 to regulate the transcription of genes that are important in cell-cycle arrest and in apoptosis. But the apoptotic pathway mediated by p53 is not fully understood. Here we show that BID, a member of the pro-apoptotic Bcl-2 family of proteins, is regulated by p53. BID mRNA is increased in a p53-dependent manner in vitro and in vivo, with strong expression in the splenic red pulp and colonic epithelium of gamma-irradiated mice. Both the human and the mouse BID genomic loci contain p53-binding DNA response elements that bind p53 and mediate p53-dependent transactivation of a reporter gene. In addition, BID-null mouse embryonic fibroblasts are more resistant than are wild-type fibroblasts to the DNA damaging agent adriamycin and the nucleotide analogue 5-fluorouracil, both of which stabilize endogenous p53. Our results indicate that BID is a p53-responsive 'chemosensitivity gene' that may enhance the cell death response to chemotherapy.
引用
收藏
页码:842 / 849
页数:8
相关论文
共 50 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]  
Attardi LD, 2000, GENE DEV, V14, P704
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]   Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo [J].
Burns, TF ;
Bernhard, EJ ;
El-Deiry, WS .
ONCOGENE, 2001, 20 (34) :4601-4612
[5]  
Chen JD, 1996, MOL CELL BIOL, V16, P2445
[6]   DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes [J].
Costanzo, A ;
Merlo, P ;
Pediconi, N ;
Fulco, M ;
Sartorelli, V ;
Cole, PA ;
Fontemaggi, G ;
Fanciulli, M ;
Schiltz, L ;
Blandino, G ;
Balsano, C ;
Levrero, M .
MOLECULAR CELL, 2002, 9 (01) :175-186
[7]   Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling [J].
El-Deiry, WS .
CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1066-1075
[8]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[9]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[10]   Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death [J].
Gross, A ;
Yin, XM ;
Wang, K ;
Wei, MC ;
Jockel, J ;
Millman, C ;
Erdjument-Bromage, H ;
Tempst, P ;
Korsmeyer, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) :1156-1163